ImmunityBio (IBRX) Equity Income (2021 - 2023)

ImmunityBio (IBRX) has 3 years of Equity Income data on file, last reported at -$1.3 million in Q3 2023.

• Equity Income for Q3 2023 came in at -$1.3 million, up 71.84% year-over-year; the trailing twelve-month figure through Jun 2024 was -$1.3 million (up 91.23% YoY), and the FY2023 annual result was -$7.5 million, up 37.65% from the prior year.
• Equity Income climbed to -$1.3 million in Q3 2023 per IBRX's latest filing, from -$4.0 million in the prior quarter.
• Over five years, Equity Income peaked at -$197000.0 in Q1 2022 and troughed at -$4.5 million in Q3 2022.
• A 3-year average of -$2.6 million and a median of -$2.9 million in 2022 frame the typical range for Equity Income.
• On a YoY basis, Equity Income climbed as much as 71.84% in 2023 and fell as far as 1086.29% in 2023.
• A 3-year view of Equity Income shows it stood at -$803000.0 in 2021, then plunged by 342.59% to -$3.6 million in 2022, then soared by 64.69% to -$1.3 million in 2023.
• Business Quant data shows IBRX's Equity Income at -$1.3 million in Q3 2023, -$4.0 million in Q2 2023, and -$2.3 million in Q1 2023.